Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies

Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP) has initiated a program to expedite the clinical development of its NR2F6 therapies by integrating modified mRNA technology with its existing siRNA intellectual property. The company has submitted an Investigational New Drug Application (IND#16928) for its drug tCellVax, designed to silence NR2F6 in human immune cells to enhance their ability to combat cancer. Regen has engaged Dyo Biotechnologies for support in this development, and is developing a new patent application to protect its innovations.

Positive

• Launch of a program to accelerate NR2F6 therapies development.
• Filing of Investigational New Drug Application (IND#16928) for tCellVax.
• Collaboration with Dyo Biotechnologies to enhance drug development.
• Potential marketable improvements through new mRNA intellectual property.

Negative

• None.

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced a program to accelerate the clinical development of its NR2F6 therapies. The Company intends to combine modified mRNA technology with Regen's existing siRNA ( small interfering RNA)  intellectual property targeting the NR2F6 nuclear receptor which has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.

mRNA is a single-stranded molecule that carries genetic code from DNA in a cell's nucleus to ribosomes (the cell's protein-making machinery).   

Regen has filed  an Investigational New Drug Application  (IND#16928) for their drug termed tCellVax   with the U.S. FDA. tCellVax is intended to utilize siRNA to silence NR2F6 activity in human immune cells thereby activating these immune cells in such a way that they can attack cancer cells. The Company believes that  adding new intellectual property utilizing modified mRNA will profoundly simplify the drug development process and thus speed development. 

Dyo Biotechnologies ( https://www.dyobiotechnologies.com ) has been contracted to assist Regen with the development of the above mentioned technology.

"I believe our tCellVax drug as it stands today is a potentially major new development in the field of cancer immunotherapy. We believe that by adding our new mRNA intellectual property to tCellVax we can simplify its administration to patients and thus create a much more marketable drug," says David Koos, CEO and Chairman of Regen. "An RNA-based checkpoint inhibitor will be a first-in-class drug."

Regen is in the process of drafting a new patent application pertaining to this intellectual property.

About Regen BioPharma Inc.: 

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION :
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com 
david.koos@regenbiopharma.com

Follow us on Twitter for future updates: https://twitter.com/TheRegenBio

View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-announces-program-to-fast-track-its-checkpoint-inhibitor-program-utilizing-modified-mrna-and-sirna-technologies-301499817.html

SOURCE Regen BioPharma, Inc.

FAQ

What is Regen BioPharma's new program announced on March 10, 2022?

Regen BioPharma's new program aims to accelerate the clinical development of NR2F6 therapies by combining modified mRNA technology with existing siRNA intellectual property.

What is tCellVax and its significance?

tCellVax is Regen's drug aimed at silencing NR2F6 in immune cells to enhance their cancer-fighting abilities, with an Investigational New Drug Application filed with the U.S. FDA.

Who is assisting Regen with the development of modified mRNA technology?

Dyo Biotechnologies has been contracted to assist Regen in the development of modified mRNA technology.

What is the potential benefit of integrating mRNA with tCellVax?

Integrating mRNA technology is expected to simplify the administration process of tCellVax, potentially making the drug more marketable.

What are the main focuses of Regen BioPharma?

Regen BioPharma focuses on advancing mRNA and small molecule therapies aimed at treating cancer and autoimmune disorders.